✦ LIBER ✦

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

✍ Scribed by J Paavonen; P Naud; J Salmerón; CM Wheeler; S-N Chow; D Apter; H Kitchener; X Castellsague; JC Teixeira; SR Skinner; J Hedrick; U Jaisamrarn; G Limson; S Garland; A Szarewski; B Romanowski; FY Aoki; TF Schwarz; WAJ Poppe; FX Bosch; D Jenkins; K Hardt; T Zahaf; D Descamps; F Struyf; M Lehtinen; G Dubin

Book ID: 117305191
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 303 KB
Volume: 374
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(09)61248-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cross-protective efficacy of HPV-16/18 A

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

✍ Cosette M Wheeler; Xavier Castellsagué; Suzanne M Garland; Anne Szarewski; Jorma 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 221 KB

Overall efficacy of HPV-16/18 AS04-adjuv

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

✍ Matti Lehtinen; Jorma Paavonen; Cosette M Wheeler; Unnop Jaisamrarn; Suzanne M G 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 486 KB

Efficacy of a prophylactic adjuvanted bi

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

✍ Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Coset 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 151 KB